Health
First RSV Vaccine Caps 60-Year Search to Stem Pervasive Lung Illness
- GSK is first company to get FDA nod, Pfizer expected to follow
- Drugmakers to compete for market analysts peg at $10 billion
This article is for subscribers only.
For 60 years, doctors and scientists searched for a vaccine against a common virus that, while sometimes deadly, is little known to the public. The hunt is over.
The US Food and Drug Administration cleared GSK Plc’s shot against respiratory syncytial virus on Wednesday. The product will go on sale in the coming weeks for older adults.